CN Patent
CN105030777A — 增强alk-tki疗效、延缓其耐药的复合物及其制剂
Assigned to Third Affiliated Hospital of TMMU · Expires 2015-11-11 · 11y expired
What this patent protects
本发明提供一种水飞蓟宾或其盐和ALK-TKI的复合物及其用途,该复合物可用于增强ALK-TKI疗效、延缓其耐药,有效地提高了ALK-TKI的治疗效果。
USPTO Abstract
本发明提供一种水飞蓟宾或其盐和ALK-TKI的复合物及其用途,该复合物可用于增强ALK-TKI疗效、延缓其耐药,有效地提高了ALK-TKI的治疗效果。
Drugs covered by this patent
- Balversa (ERDAFITINIB) · Johnson & Johnson
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.